— Biotech is back on investors' radar, and for good reason. Many large pharmaceutical companies are facing a major patent cliff, meaning billions in revenue from blockbuster drugs will need to be replaced. That creates opportunities for innovative biotech firms with promising treatments, late-stage clinical trials, and potential takeover appeal. One strategy that stood out to me is focusing on companies that are further along in drug development, where much of the early-stage risk has already been reduced. According to Eden Rahim of Next Edge Capital, six biotech names that fit that profile are: 1. Cytokinetics ($CYTK) 2. Legend Biotech ($LEGN) 3. TG Therapeutics ($TGTX) 4. Alpha Cognition ($ACOG) 5. ClearPoint Neuro ($CLPT) 6. Nektar Therapeutics ($NKTR) Biotech remains a high-risk sector, but it's also one of the few areas where a successful trial, regulatory approval, or acquisition can significantly change a company's future overnight. With innovation accelerating and Big Pharma actively looking for new growth drivers, this could be a space worth watching closely. Do you own any biotech stocks, or is the sector still too volatile for your portfolio? — This is for informational and educational purposes only.
84 views
1 Comments
Sunny Guy@coinspinner · 52m
Just buy $XDNA and $FBT and youll have the sector covered.
See the full comment section 👀Sign up for the full Blossom experience!
